{"id":45857,"date":"2014-11-06T05:44:42","date_gmt":"2014-11-06T10:44:42","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=45857"},"modified":"2014-11-06T05:44:42","modified_gmt":"2014-11-06T10:44:42","slug":"agent-could-potentially-reverse-anticoagulation-associated-with-edoxaban","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2014\/11\/06\/agent-could-potentially-reverse-anticoagulation-associated-with-edoxaban\/","title":{"rendered":"Agent Could Potentially Reverse Anticoagulation Associated with Edoxaban"},"content":{"rendered":"<p>PER977 \u2014 a cation that binds to all of the new oral anticoagulants and heparin \u2014 may help reverse the anticoagulant effects of edoxaban, according to results of <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc1411800\">an industry-conducted trial published in the <em>New England Journal of Medicine<\/em><\/a>. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel.<\/p>\n<p>Researchers studied whole-blood clotting time in 80 healthy people who were given PER977 following a dose of edoxaban. After receiving edoxaban, participants&#8217; mean whole-blood clotting time rose by 37%. But after administration of PER977, whole-blood clotting time fell to within 10% of the baseline value in 10 minutes or less, and the effect lasted for 24 hours. Participants receiving placebo took 12 to 15 hours to reach that level.<\/p>\n<p>The researchers did not observe signs of procoagulant activity with PER977, and adverse events were minimal.<\/p>\n<p>This compound may also be effective and will likely be tested in the other new oral anticoagulants, as well as unfractionated heparin and low-molecular-weight heparins.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PER977 \u2014 a cation that binds to all of the new oral anticoagulants and heparin \u2014 may help reverse the anticoagulant effects of edoxaban, according to results of an industry-conducted trial published in the New England Journal of Medicine. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel. [&hellip;]<\/p>\n","protected":false},"author":494,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495],"tags":[2418,1947,1154,2417,2416],"class_list":["post-45857","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","tag-blood-clotting","tag-edoxaban","tag-oral-anticoagulants","tag-oral-factor-xa-inhibitor","tag-per977"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/45857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/494"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=45857"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/45857\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=45857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=45857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=45857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}